# Anixa Biosciences Inc: financial statements, quarterly

ANIX · Nasdaq · CIK 715446 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/anix.md) · [Financials](/companies/anix/financials.md) · [Filings](/companies/anix/filings.md) · [Insiders](/companies/anix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001493152-25-001787.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,615 d](/filings/0001493152-25-001787.md) | [1,349](/filings/0001493152-25-009854.md) | [1,646](/filings/0001641172-25-012701.md) | [1,925](/filings/0001493152-25-013000.md) | [1,476 d](/filings/0001493152-26-001845.md) | [1,552](/filings/0001493152-26-009370.md) | [1,322](/filings/0001493152-26-028105.md) | [1,055](/filings/0001493152-26-041963.md) | [1,142 d](/filings/0001493152-26-001845.md) | [1,102](/filings/0001493152-26-009370.md) | [1,258](/filings/0001493152-26-028105.md) | [1,326](/filings/0001493152-26-041963.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,051) d](/filings/0001493152-25-001787.md) | [(3,609)](/filings/0001493152-25-009854.md) | [(3,467)](/filings/0001641172-25-012701.md) | [(3,592)](/filings/0001493152-25-013000.md) | [(3,163) d](/filings/0001493152-26-001845.md) | [(3,386)](/filings/0001493152-26-009370.md) | [(3,003)](/filings/0001493152-26-028105.md) | [(2,436)](/filings/0001493152-26-041963.md) | [(2,876) d](/filings/0001493152-26-001845.md) | [(2,716)](/filings/0001493152-26-009370.md) | [(2,647)](/filings/0001493152-26-028105.md) | [(2,737)](/filings/0001493152-26-041963.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,690) d](/filings/0001493152-25-001787.md) | [(3,255)](/filings/0001493152-25-009854.md) | [(3,139)](/filings/0001641172-25-012701.md) | [(3,277)](/filings/0001493152-25-013000.md) | [(2,883) d](/filings/0001493152-26-001845.md) | [(3,184)](/filings/0001493152-26-009370.md) | [(2,790)](/filings/0001493152-26-028105.md) | [(2,258)](/filings/0001493152-26-041963.md) | [(2,695) d](/filings/0001493152-26-001845.md) | [(2,565)](/filings/0001493152-26-009370.md) | [(2,516)](/filings/0001493152-26-028105.md) | [(2,606)](/filings/0001493152-26-041963.md) |
| Diluted EPS | $ per share | not reported | [(0.10)](/filings/0001493152-25-009854.md) | [(0.10)](/filings/0001641172-25-012701.md) | [(0.10)](/filings/0001493152-25-013000.md) | not reported | [(0.10)](/filings/0001493152-26-009370.md) | [(0.09)](/filings/0001493152-26-028105.md) | [(0.07)](/filings/0001493152-26-041963.md) | not reported | [(0.08)](/filings/0001493152-26-009370.md) | [(0.07)](/filings/0001493152-26-028105.md) | [(0.08)](/filings/0001493152-26-041963.md) |
| Basic EPS | $ per share | not reported | [(0.10)](/filings/0001493152-25-009854.md) | [(0.10)](/filings/0001641172-25-012701.md) | [(0.10)](/filings/0001493152-25-013000.md) | not reported | [(0.10)](/filings/0001493152-26-009370.md) | [(0.09)](/filings/0001493152-26-028105.md) | [(0.07)](/filings/0001493152-26-041963.md) | not reported | [(0.08)](/filings/0001493152-26-009370.md) | [(0.07)](/filings/0001493152-26-028105.md) | [(0.08)](/filings/0001493152-26-041963.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.9](/filings/0001493152-25-001787.md) | [1.0](/filings/0001493152-24-009683.md) | [1.0](/filings/0001493152-24-022573.md) | [1.2](/filings/0001493152-24-035335.md) | [1.3](/filings/0001493152-26-001845.md) | [1.1](/filings/0001493152-25-009854.md) | [1.9](/filings/0001641172-25-012701.md) | [1.5](/filings/0001493152-25-013000.md) | [1.2](/filings/0001493152-26-041963.md) | [1.5](/filings/0001493152-26-009370.md) | [1.5](/filings/0001493152-26-028105.md) | [1.4](/filings/0001493152-26-041963.md) |
| Current assets | $m | [25.4](/filings/0001493152-25-001787.md) | [25.2](/filings/0001493152-24-009683.md) | [24.2](/filings/0001493152-24-022573.md) | [22.7](/filings/0001493152-24-035335.md) | [21.4](/filings/0001493152-26-001845.md) | [18.7](/filings/0001493152-25-009854.md) | [16.8](/filings/0001641172-25-012701.md) | [17.4](/filings/0001493152-25-013000.md) | [15.9](/filings/0001493152-26-041963.md) | [15.1](/filings/0001493152-26-009370.md) | [14.7](/filings/0001493152-26-028105.md) | [14.9](/filings/0001493152-26-041963.md) |
| Total assets | $m | [25.5](/filings/0001493152-25-001787.md) | [25.4](/filings/0001493152-24-009683.md) | [24.4](/filings/0001493152-24-022573.md) | [22.9](/filings/0001493152-24-035335.md) | [21.6](/filings/0001493152-26-001845.md) | [18.9](/filings/0001493152-25-009854.md) | [17.0](/filings/0001641172-25-012701.md) | [17.7](/filings/0001493152-25-013000.md) | [16.1](/filings/0001493152-26-041963.md) | [15.2](/filings/0001493152-26-009370.md) | [14.9](/filings/0001493152-26-028105.md) | [15.1](/filings/0001493152-26-041963.md) |
| Current liabilities | $m | [2.0](/filings/0001493152-25-001787.md) | [1.7](/filings/0001493152-24-009683.md) | [1.7](/filings/0001493152-24-022573.md) | [2.0](/filings/0001493152-24-035335.md) | [2.5](/filings/0001493152-26-001845.md) | [2.0](/filings/0001493152-25-009854.md) | [1.9](/filings/0001641172-25-012701.md) | [2.1](/filings/0001493152-25-013000.md) | [2.0](/filings/0001493152-26-041963.md) | [1.2](/filings/0001493152-26-009370.md) | [1.5](/filings/0001493152-26-028105.md) | [1.7](/filings/0001493152-26-041963.md) |
| Total liabilities | $m | [2.2](/filings/0001493152-25-001787.md) | [1.8](/filings/0001493152-24-009683.md) | [1.8](/filings/0001493152-24-022573.md) | [2.2](/filings/0001493152-24-035335.md) | [2.7](/filings/0001493152-26-001845.md) | [2.2](/filings/0001493152-25-009854.md) | [2.1](/filings/0001641172-25-012701.md) | [2.2](/filings/0001493152-25-013000.md) | [2.1](/filings/0001493152-26-041963.md) | [1.4](/filings/0001493152-26-009370.md) | [1.6](/filings/0001493152-26-028105.md) | [1.9](/filings/0001493152-26-041963.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [24.3](/filings/0001493152-25-001787.md) | [24.6](/filings/0001493152-24-009683.md) | [23.6](/filings/0001493152-24-022573.md) | [21.8](/filings/0001493152-24-035335.md) | [20.0](/filings/0001493152-26-001845.md) | [17.9](/filings/0001493152-25-009854.md) | [16.1](/filings/0001641172-25-012701.md) | [16.6](/filings/0001493152-25-013000.md) | [15.2](/filings/0001493152-26-041963.md) | [15.1](/filings/0001493152-26-009370.md) | [14.5](/filings/0001493152-26-028105.md) | [14.5](/filings/0001493152-26-041963.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,969) d](/filings/0001493152-25-001787.md) | [(2,309)](/filings/0001493152-25-009854.md) | [(1,456) d](/filings/0001641172-25-012701.md) | [(2,643) d](/filings/0001493152-25-013000.md) | [(927) d](/filings/0001493152-26-001845.md) | [(2,904)](/filings/0001493152-26-009370.md) | [(1,503) d](/filings/0001493152-26-028105.md) | [(1,511) d](/filings/0001493152-26-041963.md) | [(1,255) d](/filings/0001493152-26-001845.md) | [(2,610)](/filings/0001493152-26-009370.md) | [(1,741) d](/filings/0001493152-26-028105.md) | [(1,770) d](/filings/0001493152-26-041963.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001493152-24-009683.md) | [0.0](/filings/0001493152-24-022573.md) | [0.0](/filings/0001493152-24-035335.md) | [31.4](/filings/0001493152-25-009854.md) | [31.9](/filings/0001641172-25-012701.md) | [32.1](/filings/0001493152-25-013000.md) | [32.2](/filings/0001493152-26-009370.md) | [32.2](/filings/0001493152-26-028105.md) | [32.5](/filings/0001493152-26-041963.md) | [33.2](/filings/0001493152-26-009370.md) | [33.6](/filings/0001493152-26-028105.md) | [34.2](/filings/0001493152-26-041963.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,763,802 at 2026-09-09, from the cover of the [10-Q filed 2026-09-09](/filings/0001493152-26-041963.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.